Regulation of cancer metastasis by cell-free miRNAs

Biochimica et Biophysica Acta - Reviews on Cancer

Volumn 1855, Issue 1, 2015, Pages 24-42

  Alečković, Maša ^a   Kang, Yibin ^a  

^a PRINCETON UNIVERSITY   (United States)

Author keywords

Biomarker; Body fluids; Cell free microRNA; Exosomes; Metastasis

Indexed keywords

MICRORNA; MICRORNA 105; MICRORNA 10B; MICRORNA 125B; MICRORNA 126; MICRORNA 141; MICRORNA 155; MICRORNA 16; MICRORNA 17; MICRORNA 181A; MICRORNA 195; MICRORNA 200A; MICRORNA 200B; MICRORNA 200C; MICRORNA 203; MICRORNA 20A; MICRORNA 21; MICRORNA 221; MICRORNA 222; MICRORNA 34A; MICRORNA 373; MICRORNA 375; MICRORNA 422B; MICRORNA 429; MICRORNA 520C; MICRORNA 92; MICRORNA LET 7A; MICRORNA LET 7C; MICRORNA LET 7E; UNCLASSIFIED DRUG;

BREAST MILK; CANCER GROWTH; CANCER SURVIVAL; CARCINOGENESIS; CELL FUNCTION; CEREBROSPINAL FLUID; DOWN REGULATION; EPITHELIAL MESENCHYMAL TRANSITION; EXOSOME; GENE EXPRESSION REGULATION; HUMAN; INTRACELLULAR SIGNALING; MALIGNANT NEOPLASTIC DISEASE; METASTASIS; NONHUMAN; PLEURA FLUID; REVIEW; RNA STABILITY; RNA SYNTHESIS; RNA TRANSPORT; SALIVA; SEMINAL PLASMA; TUMOR INVASION; TUMOR MICROENVIRONMENT; UPREGULATION; ANIMAL; BLOOD; CELL FREE SYSTEM; GENETICS; METABOLISM; MOLECULARLY TARGETED THERAPY; NEOPLASM METASTASIS; PATHOLOGY; PHYSIOLOGY; PROCEDURES; SECRETION (PROCESS);

ANIMALS; CELL-FREE SYSTEM; EXOSOMES; HUMANS; MICRORNAS; MOLECULAR TARGETED THERAPY; NEOPLASM METASTASIS;

EID: 84918514839     PISSN: 0304419X     EISSN: 18792561     Source Type: Journal    
DOI: 10.1016/j.bbcan.2014.10.005     Document Type: Review

References (313)

1. Gupta G.P., Massague J. Cancer metastasis: building a framework. Cell 2006, 127(4):679-695.
2. Joyce J.A., Pollard J.W. Microenvironmental regulation of metastasis. Nat. Rev. Cancer 2009, 9(4):239-252.
3. Psaila B., Lyden D. The metastatic niche: adapting the foreign soil. Nat. Rev. Cancer 2009, 9(4):285-293.
4. Peinado H., Lavotshkin S., Lyden D. The secreted factors responsible for pre-metastatic niche formation: old sayings and new thoughts. Semin. Cancer Biol. 2011, 21(2):139-146.
5. Kang Y., et al. A multigenic program mediating breast cancer metastasis to bone. Cancer Cell 2003, 3(6):537-549.
6. Lu X., et al. VCAM-1 promotes osteolytic expansion of indolent bone micrometastasis of breast cancer by engaging alpha4beta1-positive osteoclast progenitors. Cancer Cell 2011, 20(6):701-714.
7. Ell B., Kang Y. SnapShot: bone metastasis. Cell 2012, 151(3). (p. 690-690.e1).
8. Ell B., et al. Tumor-induced osteoclast miRNA changes as regulators and biomarkers of osteolytic bone metastasis. Cancer Cell 2013, 24(4):542-556.
9. Roodman G.D. Mechanisms of bone metastasis. N. Engl. J. Med. 2004, 350(16):1655-1664.
10. Guise T.A., et al. Basic mechanisms responsible for osteolytic and osteoblastic bone metastases. Clin. Cancer Res. 2006, 12(20 Pt 2):6216.
11. Juarez P., Guise T.A. TGF-beta in cancer and bone: implications for treatment of bone metastases. Bone 2011, 48(1):23-29.
12. Blanco M.A., et al. Global secretome analysis identifies novel mediators of bone metastasis. Cell Res. 2012, 22(9):1339-1355.
13. Oskarsson T., et al. Breast cancer cells produce tenascin C as a metastatic niche component to colonize the lungs. Nat. Med. 2011, 17(7):867-874.
14. Korpal M., et al. The miR-200 family inhibits epithelial-mesenchymal transition and cancer cell migration by direct targeting of E-cadherin transcriptional repressors ZEB1 and ZEB2. J. Biol. Chem. 2008, 283(22):14910-14914.
15. Kaplan R.N., et al. VEGFR1-positive haematopoietic bone marrow progenitors initiate the pre-metastatic niche. Nature 2005, 438(7069):820-827.
16. Peinado H., et al. Melanoma exosomes educate bone marrow progenitor cells toward a pro-metastatic phenotype through MET. Nat. Med. 2012, 18(6):883-891.
17. Roth C., et al. Screening for circulating nucleic acids and caspase activity in the peripheral blood as potential diagnostic tools in lung cancer. Mol. Oncol. 2011, 5(3):281-291.
18. Joosse S.A., et al. Circulating cell-free cancer-testis MAGE-A RNA, BORIS RNA, let-7b and miR-202 in the blood of patients with breast cancer and benign breast diseases. Br. J. Cancer 2014, 111(5):909-917.
19. Madhavan D., et al. Plasma DNA integrity as a biomarker for primary and metastatic breast cancer and potential marker for early diagnosis. Breast Cancer Res. Treat. 2014, 146(1):163-174.
20. Schwarzenbach H., et al. Genomic profiling of cell-free DNA in blood and bone marrow of prostate cancer patients. J. Cancer Res. Clin. Oncol. 2011, 137(5):811-819.
21. Schwarzenbach H., et al. Detection and monitoring of cell-free DNA in blood of patients with colorectal cancer. Ann. N. Y. Acad. Sci. 2008, 1137:190-196.
22. Tokuhisa Y., et al. Circulating cell-free DNA as a predictive marker for distant metastasis of hepatitis C virus-related hepatocellular carcinoma. Br. J. Cancer 2007, 97(10):1399-1403.
23. Kolesnikova E.V., et al. Circulating DNA in the blood of gastric cancer patients. Ann. N. Y. Acad. Sci. 2008, 1137:226-231.
24. Diaz L.A., Bardelli A. Liquid biopsies: genotyping circulating tumor DNA. J. Clin. Oncol. 2014, 32(6):579-586.
25. Schwarzenbach H., Hoon D.S.B., Pantel K. Cell-free nucleic acids as biomarkers in cancer patients. Nat. Rev. Cancer 2011, 11(6):426-437.
26. Mostert B., et al. Diagnostic applications of cell-free and circulating tumor cell-associated miRNAs in cancer patients. Expert. Rev. Mol. Diagn. 2011, 11(3):259-275.
27. Pantel K., Alix-Panabieres C. Real-time liquid biopsy in cancer patients: fact or fiction?. Cancer Res. 2013, 73(21):6384-6388.
28. Agostini M., et al. Circulating cell-free DNA: a promising marker of pathologic tumor response in rectal cancer patients receiving preoperative chemoradiotherapy. Ann. Surg. Oncol. 2011, 18(9):2461-2468.
29. Chen X., et al. Secreted microRNAs: a new form of intercellular communication. Trends Cell Biol. 2012, 22(3):125-132.
30. He L., et al. A microRNA component of the p53 tumour suppressor network. Nature 2007, 447(7148):1130-1134.
31. Nicoloso M.S., et al. MicroRNAs - the micro steering wheel of tumour metastases. Nat. Rev. Cancer 2009, 9(4):293-302.
32. Yong S.L., Dutta A. MicroRNAs in cancer. Annu. Rev. Pathol. Mech. 2009, 4:199-227.
33. Wiemer E.A.C. The role of microRNAs in cancer: no small matter. Eur. J. Cancer 2007, 43(10):1529-1544.
34. Garzon R., Calin G.A., Croce C.M. MicroRNAs in cancer. Annu. Rev. Med. 2009, 60:167-179.
35. Erson A.E., Petty E.M. MicroRNAs in development and disease. Clin. Genet. 2008, 74(4):296-306.
36. Mann M., et al. miRNA-based mechanism for the commitment of multipotent progenitors to a single cellular fate. Proc. Natl. Acad. Sci. U. S. A. 2010, 107(36):15804-15809.
37. He L., Hannon G.J. MicroRNAs: small RNAs with a big role in gene regulation. Nat. Rev. Genet. 2004, 5(7):522-531.
38. Mattick J.S., Makunin I.V. Non-coding RNA. Hum. Mol. Genet. 2006, 15(Spec No 1):R17-R29.
39. Bartel D.P. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 2004, 116(2):281-297.
40. Cortez M.A., et al. MicroRNAs in body fluids-the mix of hormones and biomarkers. Nat. Rev. Clin. Oncol. 2011, 8(8):467-477.
41. Weber J.A., et al. The microRNA spectrum in 12 body fluids. Clin. Chem. 2010, 56(11):1733-1741.
42. Kanemaru H., et al. The circulating microRNA-221 level in patients with malignant melanoma as a new tumor marker. J. Dermatol. Sci. 2011, 61(3):187-193.
43. Lawrie C.H., et al. Detection of elevated levels of tumour-associated microRNAs in serum of patients with diffuse large B-cell lymphoma. Br. J. Haematol. 2008, 141(5):672-675.
44. Mitchell P.S., et al. Circulating microRNAs as stable blood-based markers for cancer detection. Proc. Natl. Acad. Sci. U. S. A. 2008, 105(30):10513-10518.
45. Cocucci E., Racchetti G., Meldolesi J. Shedding microvesicles: artefacts no more. Trends Cell Biol. 2009, 19(2):43-51.
46. Roberson C.D., et al. Tumor-derived exosomes as mediators of disease and potential diagnostic biomarkers. Cancer Biomark. 2010, 8(4-5):281-291.
47. Février B., Raposo G. Exosomes: endosomal-derived vesicles shipping extracellular messages. Curr. Opin. Chem. Biol. 2004, 16(4):415-421.
48. Théry C., Zitvogel L., Amigorena S. Exosomes: composition, biogenesis and function. Nat. Rev. Immunol. 2002, 2(8):569-579.
49. Aliotta J.M., et al. Microvesicle entry into marrow cells mediates tissue-specific changes in mRNA by direct delivery of mRNA and induction of transcription. Exp. Hematol. 2010, 38(3):233-245.
50. Fidler I.J. The pathogenesis of cancer metastasis: the 'seed and soil' hypothesis revisited. Nat. Rev. Cancer 2003, 3(6):453-458.
51. Thiery J.P., Sleeman J.P. Complex networks orchestrate epithelial-mesenchymal transitions. Nat. Rev. Mol. Cell Biol. 2006, 7(2):131-142.
52. Chambers A.F., Groom A.C., MacDonald I.C. Dissemination and growth of cancer cells in metastatic sites. Nat. Rev. Cancer 2002, 2(8):563-572.
53. Podsypanina K., et al. Seeding and propagation of untransformed mouse mammary cells in the lung. Science 2008, 321(5897):1841-1844.
54. Sethi N., Kang Y. Unravelling the complexity of metastasis-molecular understanding and targeted therapies. Nat. Rev. Cancer 2011, 11(10):735-748.
55. Krol J., Loedige I., Filipowicz W. The widespread regulation of microRNA biogenesis, function and decay. Nat. Rev. Genet. 2010, 11(9):597-610.
56. Lee Y., et al. MicroRNA maturation: stepwise processing and subcellular localization. EMBO J. 2002, 21(17):4663-4670.
57. Han J., et al. The Drosha-DGCR8 complex in primary microRNA processing. Genes Dev. 2004, 18(24):3016-3027.
58. Yi R., et al. Exportin-5 mediates the nuclear export of pre-microRNAs and short hairpin RNAs. Genes Dev. 2003, 17(24):3011-3016.
59. Denli A.M., et al. Processing of primary microRNAs by the microprocessor complex. Nature 2004, 432(7014):231-235.
60. Doench J.G., Sharp P.A. Specificity of microRNA target selection in translational repression. Genes Dev. 2004, 18(5):504-511.
61. Vasudevan S., Tong Y., Steitz J.A. Switching from repression to activation: microRNAs can up-regulate translation. Science 2007, 318(5858):1931-1934.
62. Hafner M., et al. Identification of microRNAs and other small regulatory RNAs using cDNA library sequencing. Methods 2008, 44(1):3-12.
63. Meltzer P.S. Cancer genomics: small RNAs with big impacts. Nature 2005, 435(7043):745-746.
64. Calin G.A., Croce C.M. MicroRNA signatures in human cancers. Nat. Rev. Cancer 2006, 6(11):857-866.
65. Welch C., Chen Y., Stallings R.L. MicroRNA-34a functions as a potential tumor suppressor by inducing apoptosis in neuroblastoma cells. Oncogene 2007, 26(34):5017-5022.
66. He L., et al. A microRNA polycistron as a potential human oncogene. Nature 2005, 435(7043):828-833.
67. Yu S., et al. miRNA-96 suppresses KRAS and functions as a tumor suppressor gene in pancreatic cancer. Cancer Res. 2010, 70(14):6015-6025.
68. Esquela-Kerscher A., Slack F.J. Oncomirs - microRNAs with a role in cancer. Nat. Rev. Cancer 2006, 6(4):259-269.
69. Lu J., et al. MicroRNA expression profiles classify human cancers. Nature 2005, 435(7043):834-838.
70. Iorio M.V., et al. MicroRNA gene expression deregulation in human breast cancer. Cancer Res. 2005, 65(16):7065-7070.
71. Calin G.A., et al. Human microRNA genes are frequently located at fragile sites and genomic regions involved in cancers. Proc. Natl. Acad. Sci. U. S. A. 2004, 101(9):2999-3004.
72. Faraoni I., et al. miR-155 gene: a typical multifunctional microRNA. Biochim. Biophys. Acta 2009, 1792(6):497-505.
73. Greither T., et al. Elevated expression of microRNAs 155, 203, 210 and 222 in pancreatic tumors is associated with poorer survival. Int. J. Cancer 2010, 126(1):73-80.
74. Jiang S., et al. MicroRNA-155 functions as an OncomiR in breast cancer by targeting the suppressor of cytokine signaling 1 gene. Cancer Res. 2010, 70(8):3119-3127.
75. Kluiver J., et al. BIC and miR-155 are highly expressed in Hodgkin, primary mediastinal and diffuse large B cell lymphomas. J. Pathol. 2005, 207(2):243-249.
76. Pedersen I.M., et al. Onco-miR-155 targets SHIP1 to promote TNFalpha-dependent growth of B cell lymphomas. EMBO Mol. Med. 2009, 1(5):288-295.
77. Ryu J.K., et al. Aberrant MicroRNA-155 expression is an early event in the multistep progression of pancreatic adenocarcinoma. Pancreatology 2010, 10(1):66-73.
78. Volinia S., et al. A microRNA expression signature of human solid tumors defines cancer gene targets. Proc. Natl. Acad. Sci. U. S. A. 2006, 103(0027-8424 (Print)):2257-2261.
79. Roldo C., et al. MicroRNA expression abnormalities in pancreatic endocrine and acinar tumors are associated with distinctive pathologic features and clinical behavior. J. Clin. Oncol. 2006, 24(29):4677-4684.
80. Li C.L., et al. MicroRNA-155 is downregulated in gastric cancer cells and involved in cell metastasis. Oncol. Rep. 2012, 27(6):1960-1966.
81. Rokah O.H., et al. Downregulation of miR-31, miR-155, and miR-564 in chronic myeloid leukemia cells. PLoS ONE 2012, 7(4):e35501.
82. Dahiya N., et al. MicroRNA expression and identification of putative miRNA targets in ovarian cancer. PLoS ONE 2008, 3(6):e2436.
83. Levati L., et al. Altered expression of selected microRNAs in melanoma: antiproliferative and proapoptotic activity of miRNA-155. Int. J. Oncol. 2009, 35(2):393-400.
84. Levati L., et al. MicroRNA-155 targets the SKI gene in human melanoma cell lines. Pigment Cell Melanoma Res. 2011, 24(3):538-550.
85. Ceppi P., et al. Loss of miR-200c expression induces an aggressive, invasive, and chemoresistant phenotype in non-small cell lung cancer. Mol. Cancer Res. 2010, 8(9):1207-1216.
86. Eulalio A., et al. Deadenylation is a widespread effect of miRNA regulation. RNA 2009, 15(1):21-32.
87. Lundstrom K. Micro-RNA in disease and gene therapy. Curr. Drug Discov. Technol. 2011, 8(2):76-86.
88. Asangani I.A., et al. MicroRNA-21 (miR-21) post-transcriptionally downregulates tumor suppressor Pdcd4 and stimulates invasion, intravasation and metastasis in colorectal cancer. Oncogene 2008, 27(15):2128-2136.
89. Meng F., et al. MicroRNA-21 regulates expression of the PTEN tumor suppressor gene in human hepatocellular cancer. Gastroenterology 2007, 133(2):647-658.
90. Tetzlaff M.T., et al. Differential expression of miRNAs in papillary thyroid carcinoma compared to multinodular goiter using formalin fixed paraffin embedded tissues. Endocr. Pathol. 2007, 18(3):163-173.
91. Iorio M.V., et al. MicroRNA signatures in human ovarian cancer. Cancer Res. 2007, 67(18):8699-8707.
92. Ma L., Weinberg R.A. Micromanagers of malignancy: role of microRNAs in regulating metastasis. Trends Genet. 2008, 24(9):448-456.
93. Zhu S., et al. MicroRNA-21 targets tumor suppressor genes in invasion and metastasis. Cell Res. 2008, 18(3):350-359.
94. Zhu Q., et al. miR-21 promotes migration and invasion by the miR-21-PDCD4-AP-1 feedback loop in human hepatocellular carcinoma. Oncol. Rep. 2012, 27(5):1660-1668.
95. Zhu S., et al. MicroRNA-21 targets the tumor suppressor gene tropomyosin 1 (TPM1). J. Biol. Chem. 2007, 282(19):14328-14336.
96. Li T., et al. MicroRNA-21 directly targets MARCKS and promotes apoptosis resistance and invasion in prostate cancer cells. Biochem. Biophys. Res. Commun. 2009, 383(3):280-285.
97. Gabriely G., et al. MicroRNA 21 promotes glioma invasion by targeting matrix metalloproteinase regulators. Mol. Cell. Biol. 2008, 28(17):5369-5380.
98. Li J., et al. MiR-21 indicates poor prognosis in tongue squamous cell carcinomas as an apoptosis inhibitor. Clin. Cancer Res. 2009, 15(12):3998-4008.
99. Ruby J.G., et al. Large-scale sequencing reveals 21U-RNAs and additional microRNAs and endogenous siRNAs in C. elegans. Cell 2006, 127(6):1193-1207.
100. Takamizawa J., et al. Reduced expression of the let-7 microRNAs in human lung cancers in association with shortened postoperative survival. Cancer Res. 2004, 64(11):3753-3756.
101. Johnson S.M., et al. RAS is regulated by the let-7 microRNA family. Cell 2005, 120(5):635-647.
102. Mayr C., Hemann M.T., Bartel D.P. Disrupting the pairing between let-7 and Hmga2 enhances oncogenic transformation. Science 2007, 315(5818):1576-1579.
103. Koscianska E., et al. Prediction and preliminary validation of oncogene regulation by miRNAs. BMC Mol. Biol. 2007, 8:79.
104. Yu F., et al. let-7 regulates self renewal and tumorigenicity of breast cancer cells. Cell 2007, 131(6):1109-1123.
105. Ibarra I., et al. A role for microRNAs in maintenance of mouse mammary epithelial progenitor cells. Genes Dev. 2007, 21(24):3238-3243.
106. Ma L., Teruya-Feldstein J., Weinberg R.A. Tumour invasion and metastasis initiated by microRNA-10b in breast cancer. Nature 2007, 449(7163):682-688.
107. Huang Q., et al. The microRNAs miR-373 and miR-520c promote tumour invasion and metastasis. Nat. Cell Biol. 2008, 10(2):202-210.
108. Tavazoie S.F., et al. Endogenous human microRNAs that suppress breast cancer metastasis. Nature 2008, 451(7175):147-152.
109. Meister J., Schmidt M.H. miR-126 and miR-126*: new players in cancer. Sci. World J. 2010, 10:2090-2100.
110. Li A., et al. Pancreatic cancers epigenetically silence SIP1 and hypomethylate and overexpress miR-200a/200b in association with elevated circulating miR-200a and miR-200b levels. Cancer Res. 2010, 70(13):5226-5237.
111. Gregory P.A., et al. The miR-200 family and miR-205 regulate epithelial to mesenchymal transition by targeting ZEB1 and SIP1. Nat. Cell Biol. 2008, 10(5):593-601.
112. Park S.M., et al. The miR-200 family determines the epithelial phenotype of cancer cells by targeting the E-cadherin repressors ZEB1 and ZEB2. Genes Dev. 2008, 22(7):894-907.
113. Hurteau G.J., et al. Overexpression of the microRNA hsa-miR-200c leads to reduced expression of transcription factor 8 and increased expression of E-cadherin. Cancer Res. 2007, 67(17):7972-7976.
114. Burk U., et al. A reciprocal repression between ZEB1 and members of the miR-200 family promotes EMT and invasion in cancer cells. EMBO Rep. 2008, 9:582-589.
115. Korpal M., et al. Direct targeting of Sec23a by miR-200s influences cancer cell secretome and promotes metastatic colonization. Nat. Med. 2011, 17(9):1101-1108.
116. Dykxhoorn D.M., et al. miR-200 enhances mouse breast cancer cell colonization to form distant metastases. PLoS ONE 2009, 4(9).
117. Sempere L.F., et al. Altered microRNA expression confined to specific epithelial cell subpopulations in breast cancer. Cancer Res. 2007, 67(24):11612-11620.
118. Rosenwald S., et al. Validation of a microRNA-based qRT-PCR test for accurate identification of tumor tissue origin. Mod. Pathol. 2010, 23(6):814-823.
119. Rosenfeld N., et al. MicroRNAs accurately identify cancer tissue origin. Nat. Biotechnol. 2008, 26(4):462-469.
120. Ferracin M., Veronese A., Negrini M. Micromarkers: miRNAs in cancer diagnosis and prognosis. Expert. Rev. Mol. Diagn. 2010, 10(3):297-308.
121. Gallardo E., et al. miR-34a as a prognostic marker of relapse in surgically resected non-small-cell lung cancer. Carcinogenesis 2009, 30(11):1903-1909.
122. Markou A., et al. Prognostic value of mature microRNA-21 and microRNA-205 overexpression in non-small cell lung cancer by quantitative real-time RT-PCR. Clin. Chem. 2008, 54(10):1696-1704.
123. Schetter A.J., et al. MicroRNA expression profiles associated with prognosis and therapeutic outcome in colon adenocarcinoma. JAMA J. Am. Med. Assoc. 2008, 299(4):425-436.
124. Ota D., et al. Identification of recurrence-related microRNAs in the bone marrow of breast cancer patients. Int. J. Oncol. 2011, 38(4):955-962.
125. Li W., et al. Diagnostic and prognostic implications of microRNAs in human hepatocellular carcinoma. Int. J. Cancer 2008, 123(7):1616-1622.
126. Calin G.A., et al. MicroRNA profiling reveals distinct signatures in B cell chronic lymphocytic leukemias. Proc. Natl. Acad. Sci. U. S. A. 2004, 101(32):11755-11760.
127. Yang H., et al. MicroRNA expression profiling in human ovarian cancer: miR-214 induces cell survival and cisplatin resistance by targeting PTEN. Cancer Res. 2008, 68(2):425-433.
128. Weiss G.J., et al. EGFR regulation by microRNA in lung cancer: correlation with clinical response and survival to gefitinib and EGFR expression in cell lines. Ann. Oncol. 2008, 19(6):1053-1059.
129. Budhu A., et al. Identification of metastasis-related microRNAs in hepatocellular carcinoma. Hepatology 2008, 47(3):897-907.
130. Giovannetti E., et al. MicroRNA-21 in pancreatic cancer: correlation with clinical outcome and pharmacologic aspects underlying its role in the modulation of gemcitabine activity. Cancer Res. 2010, 70(11):4528-4538.
131. Rodríguez-González F.G., et al. MicroRNA-30c expression level is an independent predictor of clinical benefit of endocrine therapy in advanced estrogen receptor positive breast cancer. Breast Cancer Res. Treat. 2011, 127(1):43-51.
132. Si M.L., et al. miR-21-mediated tumor growth. Oncogene 2007, 26(19):2799-2803.
133. Meng F., et al. Involvement of human micro-RNA in growth and response to chemotherapy in human cholangiocarcinoma cell lines. Gastroenterology 2006, 130(7):2113-2129.
134. Iorio M.V., et al. MicroRNA-205 regulates HER3 in human breast cancer. Cancer Res. 2009, 69(6):2195-2200.
135. Kota J., et al. Therapeutic microRNA delivery suppresses tumorigenesis in a murine liver cancer model. Cell 2009, 137(6):1005-1017.
136. Logozzi M., et al. High levels of exosomes expressing CD63 and caveolin-1 in plasma of melanoma patients. PLoS ONE 2009, 4(4):e5219.
137. Taylor D.D., Gercel-Taylor C. MicroRNA signatures of tumor-derived exosomes as diagnostic biomarkers of ovarian cancer. Gynecol. Oncol. 2008, 110(1):13-21.
138. Antonyak M.A., et al. Cancer cell-derived microvesicles induce transformation by transferring tissue transglutaminase and fibronectin to recipient cells. Proc. Natl. Acad. Sci. U. S. A. 2011, 108(12):4852-4857.
139. Webber J., et al. Cancer exosomes trigger fibroblast to myofibroblast differentiation. Cancer Res. 2010, 70(23):9621-9630.
140. Yu S., et al. Tumor exosomes inhibit differentiation of bone marrow dendritic cells. J. Immunol. 2007, 178(11):6867-6875.
141. Chalmin F., et al. Membrane-associated Hsp72 from tumor-derived exosomes mediates STAT3-dependent immunosuppressive function of mouse and human myeloid-derived suppressor cells. J. Clin. Invest. 2010, 120(2):457-471.
142. Hood J.L., San Roman S., Wickline S.A. Exosomes released by melanoma cells prepare sentinel lymph nodes for tumor metastasis. Cancer Res. 2011, 71(11):3792-3801.
143. Skog J., et al. Glioblastoma microvesicles transport RNA and proteins that promote tumour growth and provide diagnostic biomarkers. Nat. Cell Biol. 2008, 10(12):1470-1476.
144. Yuan A., et al. Transfer of microRNAs by embryonic stem cell microvesicles. PLoS ONE 2009, 4(3).
145. Zhang H., et al. MicroRNA-9 targets matrix metalloproteinase 14 to inhibit invasion, metastasis, and angiogenesis of neuroblastoma cells. Mol. Cancer Ther. 2012, 11(7):1454-1466.
146. Zhang Y., et al. Secreted monocytic miR-150 enhances targeted endothelial cell migration. Mol. Cell 2010, 39(1):133-144.
147. Fabbri M., et al. MicroRNAs bind to Toll-like receptors to induce prometastatic inflammatory response. Proc. Natl. Acad. Sci. U. S. A. 2012, 109(31):E2110-E2116.
148. Arroyo J.D., et al. Argonaute2 complexes carry a population of circulating microRNAs independent of vesicles in human plasma. Proc. Natl. Acad. Sci. U. S. A. 2011, 108(12):5003-5008.
149. Turchinovich A., et al. Characterization of extracellular circulating microRNA. Nucleic Acids Res. 2011, 39(16):7223-7233.
150. Vickers K.C., Remaley A.T. Lipid-based carriers of microRNAs and intercellular communication. Curr. Opin. Lipidol. 2012, 23(2):91-97.
151. Valadi H., et al. Exosome-mediated transfer of mRNAs and microRNAs is a novel mechanism of genetic exchange between cells. Nat. Cell Biol. 2007, 9(6):654-659.
152. Redis R.S., et al. Cell-to-cell miRNA transfer: from body homeostasis to therapy. Pharmacol. Ther. 2012, 136(2):169-174.
153. Stoorvogel W. Functional transfer of microRNA by exosomes. Blood 2012, 119(3):646-648.
154. Mause S.F., Weber C. Microparticles: protagonists of a novel communication network for intercellular information exchange. Circ. Res. 2010, 107(9):1047-1057.
155. Caby M.P., et al. Exosomal-like vesicles are present in human blood plasma. Int. Immunol. 2005, 17(7):879-887.
156. Almqvist N., et al. Serum-derived exosomes from antigen-fed mice prevent allergic sensitization in a model of allergic asthma. Immunology 2008, 125(1):21-27.
157. Chen C.Y., Hogan M.C., Ward C.J. Purification of exosome-like vesicles from urine. Methods Enzymol. 2013, 524:225-241.
158. Taylor D.D., Gercel-Taylor C. Exosomes/microvesicles: mediators of cancer-associated immunosuppressive microenvironments. Semin. Immunopathol. 2011, 33(5):441-454.
159. Chen X., et al. Characterization of microRNAs in serum: a novel class of biomarkers for diagnosis of cancer and other diseases. Cell Res. 2008, 18(10):997-1006.
160. Gilad S., et al. Serum microRNAs are promising novel biomarkers. PLoS ONE 2008, 3(9).
161. Brase J.C., et al. Serum microRNAs as non-invasive biomarkers for cancer. Mol. Cancer 2010, 9.
162. Asaga S., et al. Direct serum assay for microRNA-21 concentrations in early and advanced breast cancer. Clin. Chem. 2011, 57(1):84-91.
163. Zheng D., et al. Plasma microRNAs as novel biomarkers for early detection of lung cancer. Int. J. Clin. Exp. Pathol. 2011, 4(6):575-586.
164. Boon R.A., Vickers K.C. Intercellular transport of MicroRNAs. Arterioscler. Thromb. Vasc. Biol. 2013, 33(2):186-192.
165. Gallo A., et al. The majority of microRNAs detectable in serum and saliva is concentrated in exosomes. PLoS ONE 2012, 7(3).
166. Wang K., et al. Export of microRNAs and microRNA-protective protein by mammalian cells. Nucleic Acids Res. 2010, 38(20):7248-7259.
167. Zhou W., et al. Cancer-secreted miR-105 destroys vascular endothelial barriers to promote metastasis. Cancer Cell 2014, 25(4):501-515.
168. Nazarenko I., et al. Cell surface tetraspanin Tspan8 contributes to molecular pathways of exosome-induced endothelial cell activation. Cancer Res. 2010, 70(4):1668-1678.
169. Al-Nedawi K., et al. Endothelial expression of autocrine VEGF upon the uptake of tumor-derived microvesicles containing oncogenic EGFR. Proc. Natl. Acad. Sci. U. S. A. 2009, 106(10):3794-3799.
170. Kobayashi M., et al. Ovarian cancer cell invasiveness is associated with discordant exosomal sequestration of Let-7 miRNA and miR-200. J. Transl. Med. 2014, 12(1):4.
171. Li C., et al. Glioma microvesicles carry selectively packaged coding and non-coding RNAs which alter gene expression in recipient cells. RNA Biol. 2013, 10(8):1333-1344.
172. King H.W., Michael M.Z., Gleadle J.M. Hypoxic enhancement of exosome release by breast cancer cells. BMC Cancer 2012, 12.
173. Zhuang G., et al. Tumour-secreted miR-9 promotes endothelial cell migration and angiogenesis by activating the JAK-STAT pathway. EMBO J. 2012, 31(17):3513-3523.
174. Gibbings D.J., et al. Multivesicular bodies associate with components of miRNA effector complexes and modulate miRNA activity. Nat. Cell Biol. 2009, 11(9):1143-1149.
175. Azmi A.S., Bao B., Sarkar F.H. Exosomes in cancer development, metastasis, and drug resistance: a comprehensive review. Cancer Metastasis Rev. 2013, 32(3-4):623-642.
176. Ostrowski M., et al. Rab27a and Rab27b control different steps of the exosome secretion pathway. Nat. Cell Biol. 2010, 12(1):19-30.
177. Hsu C., et al. Regulation of exosome secretion by Rab35 and its GTPase-activating proteins TBC1D10A-C. J. Cell Biol. 2010, 189(2):223-232.
178. Bobrie A., et al. Rab27a supports exosome-dependent and -independent mechanisms that modify the tumor microenvironment and can promote tumor progression. Cancer Res. 2012, 72(19):4920-4930.
179. Trajkovic K., et al. Ceramide triggers budding of exosome vesicles into multivesicular endosomes. Science 2008, 319(5867):1244-1247.
180. Parolini I., et al. Microenvironmental pH is a key factor for exosome traffic in tumor cells. J. Biol. Chem. 2009, 284(49):34211-34222.
181. Ji X., et al. Plasma miR-208 as a biomarker of myocardial injury. Clin. Chem. 2009, 55(11):1944-1949.
182. El-Hefnawy T., et al. Characterization of amplifiable, circulating RNA in plasma and its potential as a tool for cancer diagnostics. Clin. Chem. 2004, 50(3):564-573.
183. Morelli A.E., et al. Endocytosis, intracellular sorting, and processing of exosomes by dendritic cells. Blood 2004, 104(10):3257-3266.
184. Tian T., et al. Visualizing of the cellular uptake and intracellular trafficking of exosomes by live-cell microscopy. J. Cell. Biochem. 2010, 111(2):488-496.
185. Montecalvo A., et al. Mechanism of transfer of functional microRNAs between mouse dendritic cells via exosomes. Blood 2012, 119(3):756-766.
186. Vickers K.C., et al. MicroRNAs are transported in plasma and delivered to recipient cells by high-density lipoproteins. Nat. Cell Biol. 2011, 13(4):423-433.
187. van Schooneveld E., et al. Expression profiling of cancerous and normal breast tissues identifies microRNAs that are differentially expressed in serum from patients with (metastatic) breast cancer and healthy volunteers. Breast Cancer Res. 2012, 14(1):R34.
188. Mlcochova H., et al. Urine microRNAs as potential noninvasive biomarkers in urologic cancers. Urol. Oncol. 2014, 32(1). (p. 41.e1-9).
189. Park N.J., et al. Salivary microRNA: discovery, characterization, and clinical utility for oral cancer detection. Clin. Cancer Res. 2009, 15(17):5473-5477.
190. Teplyuk N.M., et al. MicroRNAs in cerebrospinal fluid identify glioblastoma and metastatic brain cancers and reflect disease activity. Neuro Oncol. 2012, 14(6):689-700.
191. Rabinowits G., et al. Exosomal microRNA: a diagnostic marker for lung cancer. Clin. Lung Cancer 2009, 10(1):42-46.
192. Keller A., et al. MiRNAs in lung cancer - studying complex fingerprints in patient's blood cells by microarray experiments. BMC Cancer 2009, 9:353.
193. Kim S.Y., et al. Validation of circulating miRNA biomarkers for predicting lymph node metastasis in gastric cancer. J. Mol. Diagn. 2013, 15(5):661-669.
194. Yamamoto Y., et al. MicroRNA-500 as a potential diagnostic marker for hepatocellular carcinoma. Biomarkers 2009, 14(7):529-538.
195. Heneghan H.M., et al. Circulating microRNAs as novel minimally invasive biomarkers for breast cancer. Ann. Surg. 2010, 251(3):499-505.
196. Yamada Y., et al. MiR-96 and miR-183 detection in urine serve as potential tumor markers of urothelial carcinoma: correlation with stage and grade, and comparison with urinary cytology. Cancer Sci. 2011, 102(3):522-529.
197. Wong T.S., et al. Mature miR-184 and squamous cell carcinoma of the tongue. Sci. World J. 2009, 9:130-132.
198. Roth C., et al. Circulating microRNAs as blood-based markers for patients with primary and metastatic breast cancer. Breast Cancer Res. 2010, 12(6).
199. Heneghan H.M., Miller N., Kerin M.J. Circulating microRNAs: promising breast cancer biomarkers. Breast Cancer Res. 2011, 13(1):402.
200. Moltzahn F., et al. Microfluidic-based multiplex qRT-PCR identifies diagnostic and prognostic microRNA signatures in the sera of prostate cancer patients. Cancer Res. 2011, 71(2):550-560.
201. Yin J., et al. Differential expression of serum miR-126, miR-141 and miR-21 as novel biomarkers for early detection of liver metastasis in colorectal cancer. Chin. J. Cancer Res. 2014, 26(1):95-103.
202. Chan M., et al. Identification of circulating microRNA signatures for breast cancer detection. Clin. Cancer Res. 2013, 19(16):4477-4487.
203. Yu S., et al. Circulating microRNA profiles as potential biomarkers for diagnosis of papillary thyroid carcinoma. J. Clin. Endocrinol. Metab. 2012, 97(6):2084-2092.
204. Huang V., et al. Upregulation of Cyclin B1 by miRNA and its implications in cancer. Nucleic Acids Res. 2012, 40(4):1695-1707.
205. Chen W., et al. The level of circulating miRNA-10b and miRNA-373 in detecting lymph node metastasis of breast cancer: potential biomarkers. Tumour Biol. 2013, 34(1):455-462.
206. Achberger S., et al. Circulating immune cell and microRNA in patients with uveal melanoma developing metastatic disease. Mol. Immunol. 2014, 58(2):182-186.
207. Snowdon J., et al. A pilot study of urinary microRNA as a biomarker for urothelial cancer. Can. Urol. Assoc. J. 2012, 1-5.
208. Watahiki A., et al. Plasma miRNAs as biomarkers to identify patients with castration-resistant metastatic prostate cancer. Int. J. Mol. Sci. 2013, 14(4):7757-7770.
209. Eichelser C., et al. Deregulated serum concentrations of circulating cell-free microRNAs miR-17, miR-34a, miR-155, and miR-373 in human breast cancer development and progression. Clin. Chem. 2013, 59(10):1489-1496.
210. Bryant R.J., et al. Changes in circulating microRNA levels associated with prostate cancer. Br. J. Cancer 2012, 106(4):768-774.
211. Chen J., et al. Serum microRNA expression levels can predict lymph node metastasis in patients with early-stage cervical squamous cell carcinoma. Int. J. Mol. Med. 2013, 32(3):557-567.
212. Zhao S., et al. Circulating miRNA-20a and miRNA-203 for screening lymph node metastasis in early stage cervical cancer. Genet. Test. Mol. Biomarkers 2013, 17(8):631-636.
213. Guo F., et al. Serum microRNA-92 expression in patients with ovarian epithelial carcinoma. J. Int. Med. Res. 2013, 41(5):1456-1461.
214. Si H., et al. Circulating microRNA-92a and microRNA-21 as novel minimally invasive biomarkers for primary breast cancer. J. Cancer Res. Clin. Oncol. 2012, 139(2):223-229.
215. Xu Y.Z., et al. Identification of serum microRNA-21 as a biomarker for early detection and prognosis in human epithelial ovarian cancer. Asian Pac. J. Cancer Prev. 2013, 14(2):1057-1060.
216. Ma G.J., et al. Plasma post-operative miR-21 expression in the prognosis of gastric cancers. Asian Pac. J. Cancer Prev. 2013, 14(12):7551-7554.
217. Wang Z.X., et al. Prognostic significance of serum miRNA-21 expression in human non-small cell lung cancer. J. Surg. Oncol. 2011, 104(7):847-851.
218. Liu X.G., et al. High expression of serum miR-21 and tumor miR-200c associated with poor prognosis in patients with lung cancer. Med. Oncol. 2012, 29(2):618-626.
219. Ouyang L., et al. A three-plasma miRNA signature serves as novel biomarkers for osteosarcoma. Med. Oncol. 2013, 30(1):340.
220. Yaman Agaoglu F., et al. Investigation of miR-21, miR-141, and miR-221 in blood circulation of patients with prostate cancer. Tumour Biol. 2011, 32(3):583-588.
221. Zhang H.L., et al. Serum miRNA-21: elevated levels in patients with metastatic hormone-refractory prostate cancer and potential predictive factor for the efficacy of docetaxel-based chemotherapy. Prostate 2011, 71(3):326-331.
222. Wang L.G., Gu J. Serum microRNA-29a is a promising novel marker for early detection of colorectal liver metastasis. Cancer Epidemiol. 2012, 36(1):e61-e67.
223. Greenberg E., et al. A comparative analysis of total serum miRNA profiles identifies novel signature that is highly indicative of metastatic melanoma: a pilot study. Biomarkers 2013, 18(6):502-508.
224. Wu X., et al. De novo sequencing of circulating miRNAs identifies novel markers predicting clinical outcome of locally advanced breast cancer. J. Transl. Med. 2012, 10(1).
225. Chen Q., et al. Plasma miR-122 and miR-192 as potential novel biomarkers for the early detection of distant metastasis of gastric cancer. Oncol. Rep. 2014, 31(4):1863-1870.
226. Lin Q., et al. A cluster of specified microRNAs in peripheral blood as biomarkers for metastatic non-small-cell lung cancer by stem-loop RT-PCR. J. Cancer Res. Clin. 2012, 138(1):85-93.
227. Nguyen H.C.N., et al. Expression differences of circulating microRNAs in metastatic castration resistant prostate cancer and low-risk, localized prostate cancer. Prostate 2013, 73(4):346-354.
228. Chen J., et al. Predicting distant metastasis and chemoresistance using plasma miRNAs. Med. Oncol. 2014, 31(1):799.
229. Tan Z.Q., et al. Expression and its clinical significance of hsa-miR-155 in serum of endometrial cancer. Zhonghua Fu Chan Ke Za Zhi 2010, 45(10):772-774.
230. Li C., et al. miRNA-199a-3p in plasma as a potential diagnostic biomarker for gastric cancer. Ann. Surg. Oncol. 2013, 20(Suppl. 3):S397-S405.
231. Madhavan D., et al. Circulating miRNAs as surrogate markers for circulating tumor cells and prognostic markers in metastatic breast cancer. Clin. Cancer Res. 2012, 18(21):5972-5982.
232. Cheng H., et al. Circulating plasma MiR-141 is a novel biomarker for metastatic colon cancer and predicts poor prognosis. PLoS ONE 2011, 6(3):e17745.
233. Brase J.C., et al. Circulating miRNAs are correlated with tumor progression in prostate cancer. Int. J. Cancer 2011, 128(3):608-616.
234. Zhang H.L., et al. An elevated serum miR-141 level in patients with bone-metastatic prostate cancer is correlated with more bone lesions. Asian J. Androl. 2013, 15(2):231-235.
235. Selth L.A., et al. Discovery of circulating microRNAs associated with human prostate cancer using a mouse model of disease. Int. J. Cancer 2012, 131(3):652-661.
236. Cheng H.H., et al. Circulating microRNA profiling identifies a subset of metastatic prostate cancer patients with evidence of cancer-associated hypoxia. PLoS ONE 2013, 8(7):e69239.
237. Toiyama Y., et al. Serum miR-200c is a novel prognostic and metastasis-predictive biomarker in patients with colorectal cancer. Ann. Surg. 2014, 259(4):735-743.
238. Valladares-Ayerbes M., et al. Circulating miR-200c as a diagnostic and prognostic biomarker for gastric cancer. J. Transl. Med. 2012, 10:186.
239. Jung E.J., et al. Plasma microRNA 210 levels correlate with sensitivity to trastuzumab and tumor presence in breast cancer patients. Cancer 2012, 118(10):2603-2614.
240. Schwarzenbach H., et al. Diagnostic potential of PTEN-targeting miR-214 in the blood of breast cancer patients. Breast Cancer Res. Treat. 2012, 134(3):933-941.
241. Yu J., et al. Circulating microRNA-218 was reduced in cervical cancer and correlated with tumor invasion. J. Cancer Res. Clin. Oncol. 2012, 138(4):671-674.
242. Kawaguchi T., et al. Clinical impact of circulating miR-221 in plasma of patients with pancreatic cancer. Br. J. Cancer 2013, 108(2):361-369.
243. Teixeira A.L., et al. Higher circulating expression levels of miR-221 associated with poor overall survival in renal cell carcinoma patients. Tumour Biol. 2014, 35(5):4057-4066.
244. Yu H., et al. Decreased circulating miR-375: a potential biomarker for patients with non-small-cell lung cancer. Gene 2014, 534(1):60-65.
245. Lodes M.J., et al. Detection of cancer with serum miRNAs on an oligonucleotide microarray. PLoS ONE 2009, 4(7).
246. Ohshima K., et al. Let-7 microRNA family is selectively secreted into the extracellular environment via exosomes in a metastatic gastric cancer cell line. PLoS ONE 2010, 5(10).
247. Ma L., et al. Therapeutic silencing of miR-10b inhibits metastasis in a mouse mammary tumor model. Nat. Biotechnol. 2010, 28(4):341-347.
248. Moriarty C.H., Pursell B., Mercurio A.M. miR-10b targets Tiam1: implications for Rac activation and carcinoma migration. J. Biol. Chem. 2010, 285(27):20541-20546.
249. Boufraqech M., et al. miR-145 suppresses thyroid cancer growth and metastasis and targets AKT3. Endocr. Relat. Cancer 2014, 21(4):517-531.
250. Kong W., et al. MicroRNA-155 is regulated by the transforming growth factor β/Smad pathway and contributes to epithelial cell plasticity by targeting RhoA. Mol. Cell. Biol. 2008, 28(22):6773-6784.
251. Garofalo M., et al. miR-221&222 regulate TRAIL resistance and enhance tumorigenicity through PTEN and TIMP3 downregulation. Cancer Cell 2009, 16(6):498-509.
252. Liu P., Wilson M.J. miR-520c and miR-373 upregulate MMP9 expression by targeting mTOR and SIRT1, and activate the Ras/Raf/MEK/Erk signaling pathway and NF-kappaB factor in human fibrosarcoma cells. J. Cell. Physiol. 2012, 227(2):867-876.
253. Yang K., Handorean A.M., Iczkowski K.A. MicroRNAs 373 and 520c are downregulated in prostate cancer, suppress CD44 translation and enhance invasion of prostate cancer cells in vitro. Int. J. Clin. Exp. Pathol. 2009, 2(4):361-369.
254. Han H.B., et al. Let-7c functions as a metastasis suppressor by targeting MMP11 and PBX3 in colorectal cancer. J. Pathol. 2012, 226(3):544-555.
255. Saini S., et al. Regulatory role of mir-203 in prostate cancer progression and metastasis. Clin. Cancer Res. 2011, 17(16):5287-5298.
256. Suarez Y., et al. Dicer-dependent endothelial microRNAs are necessary for postnatal angiogenesis. Proc. Natl. Acad. Sci. U. S. A. 2008, 105(37):14082-14087.
257. O'Donnell K.A., et al. c-Myc-regulated microRNAs modulate E2F1 expression. Nature 2005, 435(7043):839-843.
258. Aguda B.D., et al. MicroRNA regulation of a cancer network: consequences of the feedback loops involving miR-17-92, E2F, and Myc. Proc. Natl. Acad. Sci. U. S. A. 2008, 105(50):19678-19683.
259. Bonauer A., et al. MicroRNA-92a controls angiogenesis and functional recovery of ischemic tissues in mice. Science 2009, 324(5935):1710-1713.
260. Tang W., et al. miR-27a regulates endothelial differentiation of breast cancer stem like cells. Oncogene 2014, 33(20):2629-2638.
261. Urbich C., et al. MicroRNA-27a/b controls endothelial cell repulsion and angiogenesis by targeting semaphorin 6A. Blood 2012, 119(6):1607-1616.
262. Jiang L., et al. Sp1 mediates microRNA-29c-regulated type I collagen production in renal tubular epithelial cells. Exp. Cell Res. 2013, 319(14):2254-2265.
263. Yang T., et al. miR-29 mediates TGFbeta1-induced extracellular matrix synthesis through activation of PI3K-AKT pathway in human lung fibroblasts. J. Cell. Biochem. 2013, 114(6):1336-1342.
264. Fish J.E., et al. miR-126 regulates angiogenic signaling and vascular integrity. Dev. Cell 2008, 15(2):272-284.
265. Wang S., et al. The endothelial-specific microRNA miR-126 governs vascular integrity and angiogenesis. Dev. Cell 2008, 15(2):261-271.
266. Kuehbacher A., et al. Role of Dicer and Drosha for endothelial microRNA expression and angiogenesis. Circ. Res. 2007, 101(1):59-68.
267. Chen Y., Gorski D.H. Regulation of angiogenesis through a microRNA (miR-130a) that down-regulates antiangiogenic homeobox genes GAX and HOXA5. Blood 2008, 111(3):1217-1226.
268. Martin M.M., et al. The human angiotensin II type 1 receptor +1166 A/C polymorphism attenuates microRNA-155 binding. J. Biol. Chem. 2007, 282(33):24262-24269.
269. Martin M.M., et al. MicroRNA-155 regulates human angiotensin II type 1 receptor expression in fibroblasts. J. Biol. Chem. 2006, 281(27):18277-18284.
270. Valencia K., et al. miRNA cargo within exosome-like vesicle transfer influences metastatic bone colonization. Mol. Oncol. 2014, 8(3):689-703.
271. Kosaka N., et al. Neutral sphingomyelinase 2 (nSMase2)-dependent exosomal transfer of angiogenic microRNAs regulate cancer cell metastasis. J. Biol. Chem. 2013, 288(15):10849-10859.
272. Poliseno L., et al. MicroRNAs modulate the angiogenic properties of HUVECs. Blood 2006, 108(9):3068-3071.
273. Suarez Y., et al. Dicer dependent microRNAs regulate gene expression and functions in human endothelial cells. Circ. Res. 2007, 100(8):1164-1173.
274. Le Sage C., et al. Regulation of the p27Kip1 tumor suppressor by miR-221 and miR-222 promotes cancer cell proliferation. EMBO J. 2007, 26(15):3699-3708.
275. Lee D.Y., et al. MicroRNA-378 promotes cell survival, tumor growth, and angiogenesis by targeting SuFu and Fus-1 expression. Proc. Natl. Acad. Sci. U. S. A. 2007, 104(51):20350-20355.
276. Rana S., Malinowska K., Zöller M. Exosomal tumor microRNA modulates premetastatic organ cells. Neoplasia 2013, 15(3):281-295.
277. Grange C., et al. Microvesicles released from human renal cancer stem cells stimulate angiogenesis and formation of lung premetastatic niche. Cancer Res. 2011, 71(15):5346-5356.
278. Liu M., et al. Regulation of the cell cycle gene, BTG2, by miR-21 in human laryngeal carcinoma. Cell Res. 2009, 19(7):828-837.
279. Sayed D., et al. MicroRNA-21 targets Sprouty2 and promotes cellular outgrowths. Mol. Biol. Cell 2008, 19(8):3272-3282.
280. Galardi S., et al. miR-221 and miR-222 expression affects the proliferation potential of human prostate carcinoma cell lines by targeting p27Kip1. J. Biol. Chem. 2007, 282(32):23716-23724.
281. Krichevsky A.M., Gabriely G. miR-21: a small multi-faceted RNA. J. Cell. Mol. Med. 2009, 13(1):39-53.
282. Toiyama Y., et al. Serum miR-21 as a diagnostic and prognostic biomarker in colorectal cancer. J. Natl. Cancer Inst. 2013, 105(12):849-859.
283. Wang B., Zhang Q. The expression and clinical significance of circulating microRNA-21 in serum of five solid tumors. J. Cancer Res. Clin. Oncol. 2012, 138(10):1659-1666.
284. Wei J., et al. Identification of plasma microRNA-21 as a biomarker for early detection and chemosensitivity of non-small cell lung cancer. Chin. J. Cancer 2011, 30(6):407-414.
285. Zheng J., et al. miR-21 downregulates the tumor suppressor P12 CDK2AP1 and stimulates cell proliferation and invasion. J. Cell. Biochem. 2011, 112(3):872-880.
286. Shi L., et al. MiR-21 protected human glioblastoma U87MG cells from chemotherapeutic drug temozolomide induced apoptosis by decreasing Bax/Bcl-2 ratio and caspase-3 activity. Brain Res. 2010, 1352:255-264.
287. Rombouts K., et al. Myristoylated Alanine-Rich protein Kinase C Substrate (MARCKS) expression modulates the metastatic phenotype in human and murine colon carcinoma in vitro and in vivo. Cancer Lett. 2013, 333(2):244-252.
288. Jung T., et al. CD44v6 dependence of premetastatic niche preparation by exosomes. Neoplasia 2009, 11(10):1093-1105.
289. Finn N.A., Searles C.D. Intracellular and extracellular miRNAs in regulation of angiogenesis signaling. Curr. Angiogenesis 2012, 4(102):299-307.
290. Suarez Y., Sessa W.C. MicroRNAs as novel regulators of angiogenesis. Circ. Res. 2009, 104(4):442-454.
291. Shiiyama R., et al. Sensitive detection of melanoma metastasis using circulating microRNA expression profiles. Melanoma Res. 2013, 23(5):366-372.
292. Guo W. Concise review: breast cancer stem cells: regulatory networks, stem cell niches, and disease relevance. Stem Cells Transl. Med. 2014, 3(8):924-928.
293. Mani S.A., et al. The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell 2008, 133(4):704-715.
294. Poy, M.N., et al., A pancreatic islet-specific microRNA regulates insulin secretion. Nature, (1476-4687 (Electronic)).
295. Poy M.N., et al. miR-375 maintains normal pancreatic α- and β-cell mass. Proc. Natl. Acad. Sci. U. S. A. 2009, 14:5813-5818.
296. Szczyrba J., et al. Downregulation of Sec23A protein by miRNA-375 in prostate carcinoma. Mol. Cancer Res. 2011, 9(6):791-800.
297. Kosaka N., et al. Competitive interactions of cancer cells and normal cells via secretory microRNAs. J. Biol. Chem. 2012, 287(2):1397-1405.
298. Lim P.K., et al. Gap junction-mediated import of microRNA from bone marrow stromal cells can elicit cell cycle quiescence in breast cancer cells. Cancer Res. 2011, 71(5):1550-1560.
299. Ono M., et al. Exosomes from bone marrow mesenchymal stem cells contain a microRNA that promotes dormancy in metastatic breast cancer cells. Sci. Signal. 2014, 7(332):ra63.
300. Yang M., et al. Microvesicles secreted by macrophages shuttle invasion-potentiating microRNAs into breast cancer cells. Mol. Cancer 2011, 10:117.
301. Ma L., et al. miR-9, a MYC/MYCN-activated microRNA, regulates E-cadherin and cancer metastasis. Nat. Cell Biol. 2010, 12(3):247-256.
302. Kooijmans S.A.A., et al. Exosome mimetics: a novel class of drug delivery systems. Int. J. Nanomed. 2012, 7:1525-1541.
303. Lakhal S., Wood M.J. Exosome nanotechnology: an emerging paradigm shift in drug delivery: exploitation of exosome nanovesicles for systemic in vivo delivery of RNAi heralds new horizons for drug delivery across biological barriers. BioEssays 2011, 33(10):737-741.
304. Alvarez-Erviti L., et al. Delivery of siRNA to the mouse brain by systemic injection of targeted exosomes. Nat. Biotechnol. 2011, 29(4):341-345.
305. Marleau A.M., et al. Exosome removal as a therapeutic adjuvant in cancer. J. Transl. Med. 2012, 10(1).
306. Esquela-Kerscher A., et al. The let-7 microRNA reduces tumor growth in mouse models of lung cancer. Cell Cycle 2008, 7(6):759-764.
307. Kelnar K., et al. Quantification of therapeutic miRNA mimics in whole blood from nonhuman primates. Anal. Chem. 2014, 86(3):1534-1542.
308. Bader A.G. miR-34 - a microRNA replacement therapy is headed to the clinic. Front. Genet. 2012, 3:120.
309. Korpal M., et al. Imaging transforming growth factor-beta signaling dynamics and therapeutic response in breast cancer bone metastasis. Nat. Med. 2009, 15(8):960-966.
310. Weilbaecher K.N., Guise T.A., McCauley L.K. Cancer to bone: a fatal attraction. Nat. Rev. Cancer 2011, 11(6):411-425.
311. Krützfeldt J., et al. Silencing of microRNAs in vivo with 'antagomirs'. Nature 2005, 438(7068):685-689.
312. Pigati L., et al. Selective release of microRNA species from normal and malignant mammary epithelial cells. PLoS ONE 2010, 5(10).
313. Redova M., et al. Circulating miR-378 and miR-451 in serum are potential biomarkers for renal cell carcinoma. J. Transl. Med. 2012, 10:55.